TScan Therapeutics (TCRX)
(Delayed Data from NSDQ)
$1.72 USD
+0.12 (7.50%)
Updated Sep 18, 2025 04:00 PM ET
After-Market: $1.73 +0.01 (0.58%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Fundamental Charts
About Market Cap
As of the previous market close, TScan Therapeutics, Inc. has a market cap of $90.80M, which represents its share price of $1.60 multiplied by its outstanding shares number of 56.75M. As a small-cap company, TCRX's shareholders are generally exposed to more risk than shareholders of mid and large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
TCRX 1.72 +0.12(7.50%)
Will TCRX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for TCRX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TCRX
TScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Beats Revenue Estimates
Urogen Pharma (URGN) Reports Q2 Loss, Lags Revenue Estimates
TCRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q2 Loss, Tops Revenue Estimates
Twist Bioscience (TWST) Reports Q3 Loss, Tops Revenue Estimates
TScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Tops Revenue Estimates
Other News for TCRX
Is TCRX setting up for a drop? Reversal New Lows Setup shows up after plummeting 6.98%
H.C. Wainwright Sticks to Their Buy Rating for TScan Therapeutics (TCRX)
Is TCRX set to rally? Hammer Candlestick shows up after gaining 1.78%
Bollinger Band Squeeze appears for TCRX after 3.98% move
Tracking Baker Brothers Portfolio - Q2 2025 Update